Immuron Ltd
IMRN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMRN
Immuron Ltd is an Australian biopharmaceutical company commercializing its proprietary 'Hyper-Immune' polyclonal antibody platform, with a marketed over-the-counter product (Travelan® for traveler's diarrhea) and a clinical pipeline targeting gastrointestinal infections including C. difficile (IMM-529) and other pathogens.
Key risk: Limited cash runway
Market Cap
$9.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Tracking 1 clinical trial for Immuron Ltd.
Immuron Ltd is an Australian biopharmaceutical company commercializing its proprietary 'Hyper-Immune' polyclonal antibody platform, with a marketed over-the-counter product (Travelan® for traveler's diarrhea) and a clinical pipeline targeting gastrointestinal infections including C. difficile (IMM-529) and other pathogens.
- Global H1 FY26 sales grew to AUD$4.2 million, with U.S. market momentum (+17% YoY) [news · published 2026-02-25].
- Cash of AUD$10.0 million as of H1 FY26 (unaudited) to fund operations, including AUD$7.3 million (net) raised at an average price of A$0.0803 [news · published 2026-02-25].
- Received FDA IND approval for IMM-529 (Clostridioides difficile infection) [news · published 2026-02-25].
- Engaged Pullan Consulting to secure a strategic partnership for IMM-529 [news · published 2026-07-06].
- New U.S. Department of Defense award to develop oral therapeutics targeting Campylobacter and Shigella [news · published 2025-12-03].
What works
- Consistent revenue growth: Global H1 FY26 sales grew to AUD$4.2 million, with U.S. market showing strong momentum (+17% YoY) [news · published 2026-02-25].
- Validated platform: The 'Hyper-Immune' platform is versatile, moving beyond traveler’s diarrhea into high-value clinical targets [news · published 2026-02-25].
- FDA IND approval for IMM-529 (C. difficile) de-risks the clinical pathway and opens partnership opportunities [news · published 2026-02-25].
- New U.S. Department of Defense award supports development of two new oral therapeutics, expanding pipeline [news · published 2025-12-03].
What to weigh
- Cash of AUD$10.0 million (unaudited) as of H1 FY26 may be limited relative to the costs of advancing multiple clinical programs and seeking partnerships [news · published 2026-02-25].
- Topline results from the Travelan® P2TD Uniformed Services University study were delayed to end of November 2025 due to U.S. government shutdown [news · published 2025-10-31].
- The company is still pre-revenue from its pipeline (IMM-529, IMM-986), relying on OTC sales of Travelan® and ProIBS® for current revenue [news · published 2026-01-20].
- Dependence on securing a strategic partner for IMM-529 introduces execution risk [news · published 2026-07-06].
From the filings
Quoted directly from source documents.
Global H1 FY26 sales grew to AUD$4.2 million, with U.S. market showing strong momentum (+17% YoY)
“Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).”
News · February 25, 2026
Cash of AUD$10.0 million as of H1 FY26 (unaudited)
“Cash (AUD $10.0 million) to fund operating activities.”
News · February 25, 2026
FDA IND approval for IMM-529
“Immuron Reports HY26 Results With AUD$4.2M Sales, AUD$10M Cash, Strategic Reset And FDA IND Approval For IMM-529”
News · February 25, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of AUD$10.0M (unaudited) as of H1 FY26 may be insufficient to fund all pipeline programs without partnership or financing [news · published 2026-02-25].
- Clinical trial delays — Travelan® P2TD topline results delayed to end of November 2025 due to U.S. government shutdown [news · published 2025-10-31].
- Dependence on partnership — Securing a strategic partner for IMM-529 is critical for advancing the program; failure could stall development [news · published 2026-07-06].
- Pre-revenue pipeline — Pipeline products (IMM-529, IMM-986) have no approved products yet; revenue relies on OTC sales of Travelan® and ProIBS® [news · published 2026-01-20].
What to watch
- Topline results from the Travelan® P2TD Uniformed Services University study (delayed to end of November 2025) [news · published 2025-10-31].
- Progress of IMM-529 IND and any updates on FDA review or clinical trial initiation [news · published 2026-02-25].
- Outcome of strategic partnership efforts for IMM-529 via Pullan Consulting [news · published 2026-07-06].
- Sales growth trajectory of Travelan® and ProIBS® in upcoming quarterly reports [news · published 2026-01-20].
Sources: Competitor trials · News · Generated August 29, 2026 · How we verify sources →
Run Immuron Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immuron Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$66K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 30,574 | $24K |
| xtx topco ltd | 17,383 | $13K |
| citadel advisors llc | 13,804 | $11K |
| two sigma securities, llc | 10,906 | $8K |
| rhumbline advisers | 7,367 | $6K |
| bnp paribas financial markets | 4,600 | $4K |
| blackrock, inc. | 225 | $174 |
Short Interest
as of May 1, 2026- % of float
- 0.2%
- Days to cover
- 0.6
- Shares short
- 11,600
- Daily short volume (May 7, 2026)
- 30.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMRN short interestFrequently asked questions
What is the AI investment thesis for Immuron Ltd?
Immuron Ltd is an Australian biopharmaceutical company commercializing its proprietary 'Hyper-Immune' polyclonal antibody platform, with a marketed over-the-counter product (Travelan® for traveler's diarrhea) and a clinical pipeline targeting gastrointestinal infections including C. difficile (IMM-529) and other pathogens.
Who is the CEO of Immuron Ltd?
Mr. Steven George Lydeamore CPA, M.B.A. is the chief executive officer of Immuron Ltd (IMRN).
Where is Immuron Ltd headquartered?
Immuron Ltd (IMRN) is headquartered in Carlton, VIC, Australia.
What therapeutic areas does Immuron Ltd focus on?
Immuron Ltd develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.